Skip to content

Correlation between coagulation function, trace elements and sepsis

Study on the correlation and prognosis of coagulation function and trace elements with myocardial injury caused by sepsis

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106645
Enrollment
Unknown
Registered
2025-07-28
Start date
2024-07-01
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial injury caused by sepsis

Interventions

Sepsis patients:None
Patients with myocardial injury due to sepsis:None
Patients with myocardial injury caused by septic shock:None

Sponsors

The First Affiliated Hospital of Dalian Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. All patients were treated according to the European Intensive Care Medical Association/American Intensive Care Medical Association (ESICM/) on October 2, 2021. SCCM) published the "Campaign to Save Sepsis: International Guidelines for the Treatment of Sepsis and Septic Shock (2021)" (SSC, 2021 edition), which met the diagnostic criteria of sepsis, that is, the patients with infection or suspected infection had an increase of >= points in the organ failure score (SOFA) compared with the baseline. 2.Age > 18 years old; 3.Complete clinical data; 4.Participants in the control group were all healthy medical personnel who had no basic diseases and were over 18 years old.

Exclusion criteria

Exclusion criteria: 1.Patients admitted to hospital due to endocarditis, pericarditis or myocarditis, patients with recent primary coronary events, patients after cardiopulmonary resuscitation or heart surgery, and other diseases that affect troponin level; 2.Patients with hematological diseases such as leukemia and disseminated intravascular coagulation before diagnosis; Have a history of blood transfusion in the past 1 month; Patients who regularly use thrombolytic or anticoagulant drugs for a long time; Continuous blood purification (CBP) in recent 2 weeks; 3.pregnancy; 4.Patients with end-stage chronic liver and kidney diseases and advanced malignant tumors; 5.Patients with autoimmune diseases and after transplantation or those who take immunosuppressants and hormones for a long time; 6.Give up halfway or refer for treatment; 7.The medical history is not detailed and important clinical data cannot be provided.

Design outcomes

Primary

MeasureTime frame
Thrombomodulin;

Secondary

MeasureTime frame
Trace elements copper, iron and zinc;

Countries

China

Contacts

Public ContactLi Runjiu

The First Affiliated Hospital of Dalian Medical University

lirunjiu@dmu-1.com+86 18098876799

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026